[go: up one dir, main page]

CA3180688A1 - Systeme d'expression de rotavirus recombinants, et rotavirus recombinants - Google Patents

Systeme d'expression de rotavirus recombinants, et rotavirus recombinants

Info

Publication number
CA3180688A1
CA3180688A1 CA3180688A CA3180688A CA3180688A1 CA 3180688 A1 CA3180688 A1 CA 3180688A1 CA 3180688 A CA3180688 A CA 3180688A CA 3180688 A CA3180688 A CA 3180688A CA 3180688 A1 CA3180688 A1 CA 3180688A1
Authority
CA
Canada
Prior art keywords
coronavirus
rotavirus
seq
domain
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3180688A
Other languages
English (en)
Inventor
John Thomas Patton
Asha Ann Philip
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Bloomington
Original Assignee
Indiana University Bloomington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Bloomington filed Critical Indiana University Bloomington
Publication of CA3180688A1 publication Critical patent/CA3180688A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12341—Use of virus, viral particle or viral elements as a vector
    • C12N2720/12343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon des modes de réalisation, l'invention concerne des compositions, des méthodes, des utilisations et des procédures de fabrication destinées à des constructions de rotavirus et des compositions immunogènes de ces dernières. Certains modes de réalisation concernent des compositions qui comprennent, sans caractère limitatif, des rotavirus chimériques à utiliser dans des compositions immunogènes contre une infection par un rotavirus et contre une infection par un coronavirus chez un sujet. Selon certains modes de réalisation, des constructions à utiliser selon la présente invention peuvent être générées et utilisées, dans lesquelles un système d'expression de rotavirus comprend en outre une ou plusieurs molécules d'acide nucléique codant pour un ou plusieurs polypeptides d'un coronavirus.
CA3180688A 2020-04-20 2021-04-20 Systeme d'expression de rotavirus recombinants, et rotavirus recombinants Pending CA3180688A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063012870P 2020-04-20 2020-04-20
US63/012,870 2020-04-20
PCT/US2021/028195 WO2021216575A1 (fr) 2020-04-20 2021-04-20 Système d'expression de rotavirus recombinants, et rotavirus recombinants

Publications (1)

Publication Number Publication Date
CA3180688A1 true CA3180688A1 (fr) 2021-10-28

Family

ID=78270067

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3180688A Pending CA3180688A1 (fr) 2020-04-20 2021-04-20 Systeme d'expression de rotavirus recombinants, et rotavirus recombinants

Country Status (6)

Country Link
EP (1) EP4138904A4 (fr)
JP (1) JP2023523411A (fr)
CN (1) CN115942955A (fr)
BR (1) BR112022021259A2 (fr)
CA (1) CA3180688A1 (fr)
WO (1) WO2021216575A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020014654A1 (fr) 2018-07-13 2020-01-16 The Trustees Of Indiana University Système d'expression de rotavirus recombinants et rotavirus recombinants
US20240200099A1 (en) * 2021-04-15 2024-06-20 Merck Sharp & Dohme Llc Rotavirus vectors for heterologous gene delivery
CN116694578A (zh) * 2023-04-29 2023-09-05 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 稳定表达t7聚合酶细胞系、轮状病毒反向遗传系统及其构建方法和应用
WO2025059470A1 (fr) * 2023-09-15 2025-03-20 Board Of Regents, The University Of Texas System Antigènes du sars-cov-2 s stabilisés
CN117866858B (zh) * 2023-11-30 2024-06-21 吉林农业大学 一种表达猪轮状病毒抗原的重组植物乳杆菌及其应用
CN117904197B (zh) * 2024-01-16 2024-08-27 伊诺维康(北京)生物科技有限公司 一种羊轮状病毒感染性克隆质粒和构建方法、羊轮状病毒的反向遗传病毒拯救系统及其应用
CN117947096B (zh) * 2024-01-16 2024-08-30 伊诺维康(北京)生物科技有限公司 一种羊轮状病毒重组质粒、反向遗传病毒学拯救系统及其构建方法和应用
CN120796206B (zh) * 2025-09-18 2025-12-16 江苏省农业科学院 一种同时表达不同g型vp7的重组猪轮状病毒及其构建方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618127B1 (fr) * 2003-04-10 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Composé immunogénique d'une protéine spike du coronavirus de la SARS
WO2020014654A1 (fr) * 2018-07-13 2020-01-16 The Trustees Of Indiana University Système d'expression de rotavirus recombinants et rotavirus recombinants
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
US20240200099A1 (en) * 2021-04-15 2024-06-20 Merck Sharp & Dohme Llc Rotavirus vectors for heterologous gene delivery

Also Published As

Publication number Publication date
CN115942955A (zh) 2023-04-07
EP4138904A1 (fr) 2023-03-01
BR112022021259A2 (pt) 2022-12-27
WO2021216575A1 (fr) 2021-10-28
JP2023523411A (ja) 2023-06-05
EP4138904A4 (fr) 2024-10-09

Similar Documents

Publication Publication Date Title
CA3180688A1 (fr) Systeme d'expression de rotavirus recombinants, et rotavirus recombinants
US20250171502A1 (en) Recombinant rota virus expression system and recombinant rota viruses
US9273288B2 (en) Pseudoinfectious flavivirus and uses thereof
US20080260698A1 (en) Chimeric sindbis-western equine encephalitis virus and uses thereof
US8394620B2 (en) Two-component genome flavivirus and uses thereof
Philip et al. Generation of recombinant rotaviruses expressing human norovirus capsid proteins
CN101970645A (zh) 呼肠弧病毒家族病毒的疫苗病毒株的制造方法
US20230272405A1 (en) Flavivirus signal peptides, vaccine constructs, and methods therefor
US20250263443A1 (en) Recombinant rotavirus expressing exogenous protein and uses thereof
US20060165723A1 (en) Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
US20250041398A1 (en) A therapeutic against crimean-congo hemorrhagic fever virus
Philip et al. Rotavirus as an Expression Platform of the SARS-CoV-2 Spike Protein
CN118555965A (zh) 表达外源蛋白的重组轮状病毒及其用途
AU2014201189B2 (en) Method for producing vaccinal viral strain of a virus of the Reoviridae family
Philip Generation of Recombinant Rotaviruses as Expression Vectors of Foreign Proteins
AU2017256071B2 (en) Reoviridae vaccine
Deal Primary Peripheral Human Plasmacytoid Dendritic Cell Responses to Rotavirus Infection: Mechanisms of Induction and Consequences for Pathogenesis
HK1146490A (en) Two-component genome flavivirus and uses thereof